411 related articles for article (PubMed ID: 28317082)
1. Current Review on High-Risk Multiple Myeloma.
Chan HSH; Chen CI; Reece DE
Curr Hematol Malig Rep; 2017 Apr; 12(2):96-108. PubMed ID: 28317082
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for multiple myeloma in the era of novel therapies.
Ziogas DC; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2018 Nov; 11(11):863-879. PubMed ID: 30334460
[TBL] [Abstract][Full Text] [Related]
3. Advances in understanding prognosis in myeloma.
Smith D; Yong K
Br J Haematol; 2016 Nov; 175(3):367-380. PubMed ID: 27604166
[TBL] [Abstract][Full Text] [Related]
4. Management of high-risk Myeloma: an evidence-based review of treatment strategies.
Lehners N; Hayden PJ; Goldschmidt H; Raab MS
Expert Rev Hematol; 2016 Aug; 9(8):753-65. PubMed ID: 27337562
[TBL] [Abstract][Full Text] [Related]
5. How to Think About Risk in Myeloma.
Krishnan A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S135-8. PubMed ID: 27521310
[TBL] [Abstract][Full Text] [Related]
6. High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.
Muchtar E; Magen H; Gertz MA
Leuk Lymphoma; 2017 Jun; 58(6):1283-1296. PubMed ID: 27734720
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma: Every year a new standard?
Rajkumar SV
Hematol Oncol; 2019 Jun; 37 Suppl 1(Suppl 1):62-65. PubMed ID: 31187526
[TBL] [Abstract][Full Text] [Related]
8. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
9. Myeloma Is Not a Single Disease.
Lonial S; Nooka AK
J Oncol Pract; 2016 Apr; 12(4):287-92. PubMed ID: 27072380
[TBL] [Abstract][Full Text] [Related]
10. The next generation of novel therapies for the management of relapsed multiple myeloma.
Gonsalves WI; Milani P; Derudas D; Buadi FK
Future Oncol; 2017 Jan; 13(1):63-75. PubMed ID: 27513456
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
Stewart AK; Fonseca R
J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
[TBL] [Abstract][Full Text] [Related]
12. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
[TBL] [Abstract][Full Text] [Related]
14. Clonal Evolution in Multiple Myeloma.
Fakhri B; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S130-4. PubMed ID: 27521309
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
Rajkumar SV; Buadi F
Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
[TBL] [Abstract][Full Text] [Related]
16. Emerging options for combination therapy in multiple myeloma.
Rossi AC
Clin Adv Hematol Oncol; 2018 Mar; 16(3):192-194. PubMed ID: 29742074
[No Abstract] [Full Text] [Related]
17. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma.
Paner A; Patel P; Dhakal B
Blood Rev; 2020 May; 41():100643. PubMed ID: 31818702
[TBL] [Abstract][Full Text] [Related]
18. Outcome of allogeneic transplantation in newly diagnosed and relapsed/refractory multiple myeloma: long-term follow-up in a single institution.
Franssen LE; Raymakers RA; Buijs A; Schmitz MF; van Dorp S; Mutis T; Lokhorst HM; van de Donk NW
Eur J Haematol; 2016 Nov; 97(5):479-488. PubMed ID: 27028304
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
[TBL] [Abstract][Full Text] [Related]
20. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome.
Kleber M; Ihorst G; Gross B; Koch B; Reinhardt H; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):541-51. PubMed ID: 23810244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]